The Justice Department has taken a substantial leap to sue CVS Pharmacy Inc., accusing the retail giant of routinely ignoring federal laws by filling prescriptions that were neither valid nor for a legitimate medical purpose. This lawsuit, filed in Providence, Rhode Island, and recently made public, suggests that the nation's largest pharmacy chain played a critical role in exacerbating the opioid crisis. A significant detail revealed involves CVS pharmacists allegedly dispensing "trinity" prescriptions, a potent mix of opioids, benzodiazepines, and muscle relaxants commonly abused and known for their dangerous side effects.
According to the Justice Department's allegations, CVS's corporate policies prioritized profit over patient health and safety, creating a work environment with overwhelming performance metrics and understaffed pharmacies. These conditions reportedly led to the unlawful dispensing of controlled substances, including opioid prescriptions far beyond safe, medically advised limits. Principal Deputy Assistant Attorney General Brian M. Boynton stated, "Our complaint alleges that CVS repeatedly filled controlled substance prescriptions that were unlawful and pressured its pharmacists to fill such prescriptions without taking the time needed to confirm their validity."
Some of the shocking allegations point to CVS knowingly filling prescriptions from providers recognized for participating in "pill mill" activities. These are healthcare professionals who prescribe controlled substances indiscriminately, without medical justification. The federal government's readiness to intervene reflects its commitment to address healthcare fraud aggressively and safeguard public health. U.S. Attorney Zachary A. Cunha specifically mentioned the destruction opioid deaths have wrought on communities and admonished any corporation that "prize profits over patient safety," as noted by the Justice Department.
Moreover, the lawsuit encompasses the violation of both the Controlled Substances Act (CSA) and the False Claims Act (FCA). This dual approach targets CVS's alleged failure to adhere to prescription legality and its action of seeking reimbursements from federal healthcare programs for these unlawfully filled prescriptions. The court's future decisions may impose civil penalties for each infraction under CSA and treble damages under the FCA, as well as possibly mandating changes to CVS’s corporate compliance programs and policies. U.S. Attorney Jessica D. Aber highlighted the broad scope of the law, underscoring that it applies to everyone, from street-level dealers to major corporations, inferring no entity is above accountability.
This case first came to light via a whistleblower, Hillary Estright, a former CVS employee. Estright filed under the qui tam provisions of the False Claims Act in 2019. Such provisions encourage individuals to report illicit activities by allowing them to sue on behalf of the United States and potentially share in any recovery obtained. With this intervention unfolding, we're witnessing the government’s broader strategy to clamp down on health care fraud and ensure that individuals and entities alike are held to account for their part in perpetuating the opioid crisis.
